Updated efficacy and safety data from the phase 2 NP28761 study of alectinib in ALK-positive non-small-cell lung cancer Meeting Abstract
| Authors: | Camidge, D. R.; Gadgeel, S.; Ou, S. H.; Gandhi, L.; Riely, G.; Cetnar, J.; West, H.; Socinski, M.; Chiappori, A.; Mekhail, T.; Chao, B.; Borghaei, H.; Gold, K.; Bordogna, W.; Balas, B.; Noe, J.; Golding, S.; Zeaiter, A.; Shaw, A. |
| Abstract Title: | Updated efficacy and safety data from the phase 2 NP28761 study of alectinib in ALK-positive non-small-cell lung cancer |
| Meeting Title: | IASLC 17th World Conference on Lung Cancer |
| Keywords: | us; nsclc; alectinib; alk-inhibitor |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 12 |
| Issue: | 1 Suppl. |
| Meeting Dates: | 2016 Dec 4-7 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2017-01-01 |
| Start Page: | S378 |
| Language: | English |
| ACCESSION: | WOS:000413055800407 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jtho.2016.11.426 |
| Notes: | Meeting Abstract: MA07.02 -- Source: Wos |
